78 related articles for article (PubMed ID: 28476786)
1. Amphiregulin as a Novel Resistance Factor for Amrubicin in Lung Cancer Cells.
Tokunaga S; Nagano T; Kobayashi K; Katsurada M; Nakata K; Yamamoto M; Tachihara M; Kamiryo H; Yokozaki H; Nishimura Y
Anticancer Res; 2017 May; 37(5):2225-2231. PubMed ID: 28476786
[TBL] [Abstract][Full Text] [Related]
2. Over-expression of MDR1 in amrubicinol-resistant lung cancer cells.
Takakuwa O; Oguri T; Ozasa H; Uemura T; Kasai D; Miyazaki M; Maeno K; Sato S
Cancer Chemother Pharmacol; 2011 Sep; 68(3):669-76. PubMed ID: 21128075
[TBL] [Abstract][Full Text] [Related]
3. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
Hira A; Watanabe H; Maeda Y; Yokoo K; Sanematsu E; Fujii J; Sasaki J; Hamada A; Saito H
Biochem Pharmacol; 2008 Feb; 75(4):973-80. PubMed ID: 18054347
[TBL] [Abstract][Full Text] [Related]
4. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.
Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K
Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients.
Makino Y; Watanabe M; Makihara RA; Nokihara H; Yamamoto N; Ohe Y; Sugiyama E; Sato H; Hayashi Y
Asia Pac J Clin Oncol; 2016 Sep; 12(3):259-64. PubMed ID: 26948073
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines: Potential for combination therapy.
Hatakeyama Y; Kobayashi K; Nagano T; Tamura D; Yamamoto M; Tachihara M; Kotani Y; Nishimura Y
Cancer Lett; 2014 Feb; 343(1):74-9. PubMed ID: 24139969
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial.
Kitagawa C; Saka H; Kajikawa S; Mori K; Oki M; Suzuki R
Cancer Chemother Pharmacol; 2012 May; 69(5):1379-85. PubMed ID: 22237957
[TBL] [Abstract][Full Text] [Related]
8. Additive effects of amrubicin with cisplatin on human lung cancer cell lines.
Yamauchi S; Kudoh S; Kimura T; Hirata K; Yoshikawa J
Osaka City Med J; 2002 Jun; 48(1):69-76. PubMed ID: 12375699
[TBL] [Abstract][Full Text] [Related]
9. C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.
Takakuwa O; Oguri T; Ozasa H; Uemura T; Kunii E; Kasai D; Miyazaki M; Maeno K; Sato S
J Thorac Oncol; 2011 Nov; 6(11):1826-32. PubMed ID: 21964527
[TBL] [Abstract][Full Text] [Related]
10. The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells.
Takigawa N; Takeyama M; Shibayama T; Tada A; Kawata N; Okada C; Aoe K; Kozuki T; Hotta K; Tabata M; Kiura K; Ueoka H; Tanimoto M; Takahashi K
Oncol Rep; 2006 Apr; 15(4):837-42. PubMed ID: 16525668
[TBL] [Abstract][Full Text] [Related]
11. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
Suyama H; Igishi T; Ueda Y; Shigeoka Y; Kodani M; Morita M; Takeda K; Sumikawa T; Nakazaki H; Matsunami K; Matsumoto S; Shimizu E
Oncol Rep; 2010 Jan; 23(1):217-22. PubMed ID: 19956885
[TBL] [Abstract][Full Text] [Related]
14. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite.
Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
Jpn J Cancer Res; 1998 Oct; 89(10):1055-60. PubMed ID: 9849585
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.
Hayashi S; Hatashita M; Matsumoto H; Shioura H; Kitai R; Kano E
Int J Mol Med; 2006 Nov; 18(5):909-15. PubMed ID: 17016621
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer.
Watanabe H; Ikesue H; Oshiro M; Nagata K; Mishima K; Takada A; Suetsugu K; Sueyasu M; Egashira N; Harada T; Takayama K; Nakanishi Y; Oishi R
Chemotherapy; 2012; 58(6):419-25. PubMed ID: 23295219
[TBL] [Abstract][Full Text] [Related]
17. Modification of thermosensitivity by amrubicin or amrubicinol in human lung adenocarcinoma A549 cells and the kinetics of apoptosis and necrosis induction.
Hayashi S; Hatashita M; Matsumoto H; Jin ZH; Shioura H; Kano E
Int J Mol Med; 2005 Sep; 16(3):381-7. PubMed ID: 16077943
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients.
Matsunaga Y; Hamada A; Okamoto I; Sasaki J; Moriyama E; Kishi H; Matsumoto M; Hira A; Watanabe H; Saito H
Ther Drug Monit; 2006 Feb; 28(1):76-82. PubMed ID: 16418698
[TBL] [Abstract][Full Text] [Related]
19. Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.
Kneissl J; Keller S; Lorber T; Heindl S; Keller G; Drexler I; Hapfelmeier A; Höfler H; Luber B
Int J Oncol; 2012 Aug; 41(2):733-44. PubMed ID: 22614881
[TBL] [Abstract][Full Text] [Related]
20. [A case of relapsed small-cell lung cancer successfully treated by administration of amrubicin].
Mori H; Tanaka H
Nihon Kokyuki Gakkai Zasshi; 2007 Dec; 45(12):967-70. PubMed ID: 18186244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]